PT3490535T - Composição de libertação sustentada compreendendo tolcapona micronizada - Google Patents
Composição de libertação sustentada compreendendo tolcapona micronizadaInfo
- Publication number
- PT3490535T PT3490535T PT177433588T PT17743358T PT3490535T PT 3490535 T PT3490535 T PT 3490535T PT 177433588 T PT177433588 T PT 177433588T PT 17743358 T PT17743358 T PT 17743358T PT 3490535 T PT3490535 T PT 3490535T
- Authority
- PT
- Portugal
- Prior art keywords
- sustained release
- release composition
- tolcapone
- micronized
- micronized tolcapone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16382372.7A EP3275433A1 (en) | 2016-07-29 | 2016-07-29 | Sustained release composition comprising micronized tolcapone |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3490535T true PT3490535T (pt) | 2021-09-30 |
Family
ID=56571284
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177433588T PT3490535T (pt) | 2016-07-29 | 2017-07-28 | Composição de libertação sustentada compreendendo tolcapona micronizada |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11883538B2 (enExample) |
| EP (2) | EP3275433A1 (enExample) |
| JP (1) | JP7047236B2 (enExample) |
| KR (1) | KR102484678B1 (enExample) |
| CN (1) | CN109789100A (enExample) |
| AU (1) | AU2017303333B2 (enExample) |
| DK (1) | DK3490535T3 (enExample) |
| ES (1) | ES2891355T3 (enExample) |
| MX (1) | MX391116B (enExample) |
| PT (1) | PT3490535T (enExample) |
| RU (1) | RU2750670C2 (enExample) |
| WO (1) | WO2018019997A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024081554A2 (en) * | 2022-10-10 | 2024-04-18 | Corino Therapeutics, Inc. | Modified release tolcapone formulations |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236952A (en) | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
| DE69733752T2 (de) | 1996-05-20 | 2006-06-01 | G.D. Searle Llc, Chicago | Arzneimittel enthaltend oxaprozin-natriumsalz,-kaliumsalz, oder-tris(hydroxymethyl)aminomethansalz |
| WO1999052504A1 (en) * | 1998-04-09 | 1999-10-21 | F. Hoffmann-La Roche Ag | Process for the manufacture of (sub)micron sized particles by dissolving in compressed gas and surfactants |
| US6599530B2 (en) * | 1998-09-14 | 2003-07-29 | Orion Corporation | Oral compacted composition comprising catechol derivatives |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| CA2510320C (en) * | 2002-12-20 | 2012-10-09 | St. James Associates Llc/Faber Research Series | Coated particles for sustained-release pharmaceutical administration |
| EP2335696A1 (en) * | 2005-06-08 | 2011-06-22 | Orion Corporation | An entacapone-containing oral dosage form |
| WO2008087882A1 (ja) | 2007-01-15 | 2008-07-24 | Kissei Pharmaceutical Co., Ltd. | 胃内滞留型レボドパ徐放性製剤 |
| SI2640358T1 (en) * | 2010-11-15 | 2018-05-31 | Neuroderm Ltd. | Continuous administration of L-dopa, dopamine decarboxylase inhibitors, catechol-O-methyl transferase inhibitors, and compositions thereof |
| MX355309B (es) | 2011-03-14 | 2018-04-16 | Boehringer Ingelheim Int | Inhibidores de benzodioxano de la produccion de leucotrieno. |
| WO2013060668A1 (en) * | 2011-10-24 | 2013-05-02 | Som Innovation Biotech, S.L. | New therapy for transthyretin-associated amyloidosis |
| US20130195973A1 (en) * | 2012-01-30 | 2013-08-01 | Ranbaxy Laboratories Limited | Extended release pharmaceutical dosage forms of carbidopa and levodopa and process of preparation thereof |
| CN105209029A (zh) * | 2013-03-13 | 2015-12-30 | 纽罗德姆有限公司 | 帕金森病的治疗方法 |
| ES2957768T3 (es) * | 2013-11-05 | 2024-01-25 | Synagile Corp | Suministro continuo de fármacos a través de la boca |
| CA3175785A1 (en) * | 2014-09-04 | 2016-03-10 | Intrance International Ab | Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof |
-
2016
- 2016-07-29 EP EP16382372.7A patent/EP3275433A1/en not_active Withdrawn
-
2017
- 2017-07-28 CN CN201780060604.7A patent/CN109789100A/zh active Pending
- 2017-07-28 ES ES17743358T patent/ES2891355T3/es active Active
- 2017-07-28 DK DK17743358.8T patent/DK3490535T3/da active
- 2017-07-28 AU AU2017303333A patent/AU2017303333B2/en active Active
- 2017-07-28 WO PCT/EP2017/069168 patent/WO2018019997A1/en not_active Ceased
- 2017-07-28 EP EP17743358.8A patent/EP3490535B1/en active Active
- 2017-07-28 PT PT177433588T patent/PT3490535T/pt unknown
- 2017-07-28 MX MX2019001190A patent/MX391116B/es unknown
- 2017-07-28 RU RU2019103647A patent/RU2750670C2/ru active
- 2017-07-28 KR KR1020197004664A patent/KR102484678B1/ko active Active
- 2017-07-28 US US16/321,336 patent/US11883538B2/en active Active
- 2017-07-28 JP JP2019526375A patent/JP7047236B2/ja active Active
-
2024
- 2024-01-29 US US18/425,739 patent/US12220487B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2019103647A (ru) | 2020-08-28 |
| JP7047236B2 (ja) | 2022-04-05 |
| KR102484678B1 (ko) | 2023-01-03 |
| US20190167596A1 (en) | 2019-06-06 |
| MX391116B (es) | 2025-03-21 |
| EP3275433A1 (en) | 2018-01-31 |
| EP3490535A1 (en) | 2019-06-05 |
| KR20190034563A (ko) | 2019-04-02 |
| US11883538B2 (en) | 2024-01-30 |
| AU2017303333B2 (en) | 2023-03-30 |
| JP2019523305A (ja) | 2019-08-22 |
| RU2019103647A3 (enExample) | 2020-10-12 |
| US20240216282A1 (en) | 2024-07-04 |
| EP3490535B1 (en) | 2021-07-14 |
| MX2019001190A (es) | 2019-09-06 |
| AU2017303333A1 (en) | 2019-03-14 |
| CA3032211A1 (en) | 2018-02-01 |
| US12220487B2 (en) | 2025-02-11 |
| DK3490535T3 (da) | 2021-10-04 |
| WO2018019997A1 (en) | 2018-02-01 |
| BR112019001826A2 (pt) | 2019-05-07 |
| ES2891355T3 (es) | 2022-01-27 |
| CN109789100A (zh) | 2019-05-21 |
| RU2750670C2 (ru) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252425A0 (en) | Methods for activating parkin ligase and preparations | |
| IL250568B (en) | Anti-methanogenic preparations and their uses | |
| GB201412709D0 (en) | Improved binder compositions and uses thereof | |
| GB201412706D0 (en) | Improved binder compositions and uses thereof | |
| IL264446A (en) | Compounds and compositions and their use | |
| PL3099381T3 (pl) | Kompozycje środków zapachowych o przedłużonym uwalnianiu | |
| GB201502002D0 (en) | Uses and compositions | |
| IL263040A (en) | Pharmaceutical composition comprising eteplirsen | |
| GB201608762D0 (en) | Compositions and uses thereof | |
| IL260050B (en) | Dendrimers and preparations containing them | |
| IL270273B1 (en) | Highly charged drug formulations with enhanced sustained release | |
| SG10202100751YA (en) | Compounds and compositions and uses thereof | |
| IL249695A0 (en) | Converted polymyxins and preparations containing them | |
| GB201501991D0 (en) | Uses and compositions | |
| GB201502026D0 (en) | Uses and compositions | |
| ZA201901222B (en) | Composition comprising duddingtonia flagrans | |
| HUE065294T2 (hu) | Késleltetett nyújtott hatóanyag-leadású gyógyszerkészítmények | |
| GB201614897D0 (en) | Compositions and uses thereof | |
| PT3490535T (pt) | Composição de libertação sustentada compreendendo tolcapona micronizada | |
| IL248863A0 (en) | Preparations containing il-31 and their use | |
| GB201511886D0 (en) | Uses and compositions | |
| IL261544B (en) | Lipid preparations and their uses | |
| PL3424500T3 (pl) | Kompozycja farmaceutyczna zawierająca famitynib | |
| GB201602409D0 (en) | Compositions and uses thereof | |
| GB201522814D0 (en) | Compositions and uses thereof |